<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41897">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01949324</url>
  </required_header>
  <id_info>
    <org_study_id>NTMT-02</org_study_id>
    <nct_id>NCT01949324</nct_id>
  </id_info>
  <brief_title>A Phase 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel)</brief_title>
  <official_title>A Phase 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurotech Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lowy Medical Research Institute (LMRI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The EMMES Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke Reading Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neurotech Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Australia: Therapeutic Goods Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase 2, randomized, multi-center, single-masked study to evaluate the
      efficacy and safety of the NT-501 implants in participants with Mactel.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ellipsoid zone (area of IS/OS loss) as measured by en face imagining by SDOCT in study eye(s)</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in the ellipsoid zone (area of IS/OS loss) from baseline to month 24 as measured by en face imaging by SDOCT in study eye(s)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ellipsoid zone</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in the ellipsoid zone from baseline to Month 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal sensitivity (dB) as measured by microperimetry</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in retinal sensitivity (dB) as measured by microperimetry from baseline to Months 12 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in ellipsoid zone</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of study eyes with a 35% or more increase from baseline in the ellipsoid zone at Months 12 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in best corrected visual acuity (BCVA) from baseline to Months 12 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>12 and 24 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of study eyes with 15 or more letter loss from baseline in BCVA at Months 12 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>12 and 24 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of study eyes with 10 or more letter loss from baseline in BCVA at Months 12 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reading Speed</measure>
    <time_frame>12 and 24 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in reading speed as measured by the IReST from baseline to Months 12 and 24.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cone density as measured by AOSLO</measure>
    <time_frame>12 and 24 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in cone density as measured by AOSLO from baseline to Months 12 and 24, in selected participants.</description>
  </other_outcome>
  <other_outcome>
    <measure>National Eye Institute Visual Functioning Questionnaire</measure>
    <time_frame>12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in NEI VFQ (overall and subscale) from baseline to Months 12 and 24.</description>
  </other_outcome>
  <other_outcome>
    <measure>Electroretinogram changes</measure>
    <time_frame>6, 12 and 24 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Electroretinogram (ERG) changes from baseline to Months 6, 12 and 24, in selected clinics/participants.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Macular Telangiectasia Type 2</condition>
  <arm_group>
    <arm_group_label>NT-501 Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigational product is the NT-501 encapsulated cell system which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that were derived from the NTC-200 cell line by genetic modification so as to secrete recombinant human ciliary neurotrophic factor (CNTF).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham procedure</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Non-penetrating sham procedure to mimic implant procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ciliary neurotrophic factor (CNTF)</intervention_name>
    <arm_group_label>NT-501 Implant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Surgery to implant device for NT-501 arm and sham surgery for Sham arm</description>
    <arm_group_label>NT-501 Implant</arm_group_label>
    <arm_group_label>Sham procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must be offered sufficient opportunity to review and to understand the
             informed consent form, agree to the form's contents and sign the protocol's informed
             consent

          -  Participant must have at least one study eye with a positive diagnosis of MacTel Type
             2

          -  Participant must have an IS/OS PR break in the study eye(s) and en face ellipsoid
             zone (area of IS/OS loss) as measured by SDOCT between 0.16 mm2 and 4.00 mm2

          -  If female, participant must be incapable of pregnancy

          -  If male, participant must agree to use an effective form of birth control during the
             study

        Exclusion Criteria:

          -  Participant is unable to provide informed consent

          -  Participant is less than 21 years of age or greater than 80 years of age

          -  Participant is medically unable to comply with study procedures or follow-up visits

          -  Participant was a study subject in any other clinical trial of an intervention (drug
             or device) within the last 6 months

          -  Participant is pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Trombley</last_name>
    <email>jtrombley@lmri.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jules Stein Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Steven Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Philip Rosenfeld, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Eye Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Henry Wiley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan, Kellogg Eye Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Grant Comer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Barbara Blodi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Save Sight Institute</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark Gillies, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Eye Research Australia</name>
      <address>
        <city>East Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robyn Guymer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lions Eye Institute</name>
      <address>
        <city>Nedlands (Perth)</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ian Constable, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://mactelresearch.org/</url>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>September 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MacTel</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
